1. Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
   Kai Naumann et al, 2013, Clinical and Developmental Immunology CrossRef
2. TLR3 Plays Significant Roles against HBV-Associated HCC
   Xiao-lan Chen et al, 2015, Gastroenterology Research and Practice CrossRef
3. Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant
   Bo Jin et al, 2010, Journal of Biomedicine and Biotechnology CrossRef
4. Toll-like receptors in pathophysiology of liver diseases
   Safak Kiziltas, 2016, WJH CrossRef
5. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?
   Jorge André Gomes Lopes, 2016, WJH CrossRef
6. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy
   Yinglu Feng et al, 2018, OncoImmunology CrossRef
7. Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
   Apriliana E. R. Kartikasari et al, 2019, Front. Immunol. CrossRef
8. Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors
   D. M. Abarca-Merlin et al, 2019, BioMed Research International CrossRef
9. Cell Surface Expression of Endosomal Toll-Like Receptors—A Necessity or a Superfluous Duplication?
   Matylda Barbara Mielcarska et al, 2021, Front. Immunol. CrossRef
10. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
    Stefania Cuzzubbo et al, 2021, Front. Immunol. CrossRef
11. Roles of Toll-Like Receptor 3 in Human Tumors
    Xin Zheng et al, 2021, Front. Immunol. CrossRef
12. Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
    Yang Yang et al, 2022, Front. Immunol. CrossRef
13. Liposomes-Encapsulating Double-Stranded Nucleic Acid (Poly I:C) for Head and Neck Cancer Treatment
    Vidit Singh et al, 2024, ACS Pharmacol. Transl. Sci. CrossRef